EU Orphan Drug Status Sought for Nova Therapy Using Hallucinogenic Psilocybin

EU Orphan Drug Status Sought for Nova Therapy Using Hallucinogenic Psilocybin

303604

EU Orphan Drug Status Sought for Nova Therapy Using Hallucinogenic Psilocybin

Nova Mentis is seeking orphan drug designation from the European Medicines Agency (EMA) for psilocybin, its investigational therapy for fragile X syndrome. Psilocybin, found naturally in certain mushrooms — popularly called “magic mushrooms” — is most known for its hallucinogenic, anxiolytic, and psychoactive effects. However, Nova officials said in a press release announcing the filing that their compound has been shown to be effective “without apparent psychedelic side effects.” The biotech company recently filed its application…

You must be logged in to read/download the full post.